NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis $5.28 +0.03 (+0.57%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$5.06▼$5.3350-Day Range$3.19▼$5.2552-Week Range$1.96▼$5.33Volume21,912 shsAverage Volume238,283 shsMarket Capitalization$298.29 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside32.6% Upside$7.00 Price TargetShort InterestBearish10.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.39Based on 3 Articles This WeekInsider TradingSelling Shares$3.46 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.02) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector724th out of 924 stocksPharmaceutical Preparations Industry332nd out of 426 stocks 3.2 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.71% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 17.3, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently increased by 16.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 3.6 News and Social Media Coverage News SentimentDesign Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Design Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for DSGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,463,214.00 in company stock.Percentage Held by Insiders31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Design Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.To watch his fascinating interview which has taken Wall Street by storm, click here. About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesAugust 13, 2024 | insidertrades.comArsani William Sells 814,874 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockAugust 17, 2024 | finance.yahoo.comWith 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investorsAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 13, 2024 | americanbankingnews.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director Arsani William Sells 814,874 Shares of StockAugust 12, 2024 | msn.comGenerative AI vs. cancer: Absci partners with Memorial Sloan Kettering for new therapeuticsAugust 5, 2024 | globenewswire.comDesign Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioMay 25, 2024 | finanznachrichten.deDesign Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.May 20, 2024 | msn.comLarimar stock rallies 24% on FDA removal of partial clinical holdMay 10, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 10, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 9, 2024 | msn.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 7, 2024 | msn.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | globenewswire.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+33.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.79% Return on Assets-19.89% Debt Debt-to-Equity RatioN/A Current Ratio38.61 Quick Ratio38.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book1.06Miscellaneous Outstanding Shares56,495,000Free Float38,869,000Market Cap$296.60 million OptionableOptionable Beta1.83 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $704.1kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $554.01kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Jae B. Kim FACC (Age 54)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITAtai Life SciencesNASDAQ:ATAIVoyager TherapeuticsNASDAQ:VYGRSangamo TherapeuticsNASDAQ:SGMOBurning Rock BiotechNASDAQ:BNRView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 397,285 shares on 8/19/2024Ownership: 1.754%Almitas Capital LLCBought 227,180 shares on 8/16/2024Ownership: 2.218%Frazier Life Sciences Management L.P.Bought 1,195,179 shares on 8/16/2024Ownership: 2.116%Marshall Wace LLPBought 24,280 shares on 8/14/2024Ownership: 0.043%Cubist Systematic Strategies LLCBought 10,113 shares on 8/14/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions How have DSGN shares performed this year? Design Therapeutics' stock was trading at $2.65 at the beginning of the year. Since then, DSGN shares have increased by 99.2% and is now trading at $5.28. View the best growth stocks for 2024 here. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its earnings results on Monday, August, 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' top institutional shareholders include Almitas Capital LLC (2.22%), Frazier Life Sciences Management L.P. (2.12%), Point72 Asset Management L.P. (1.75%) and Acadian Asset Management LLC (1.03%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad, Stella Xu and Arsani William. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact ...Crypto 101 Media | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
